A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

  1. Del Campo, J.M.
  2. Birrer, M.
  3. Davis, C.
  4. Fujiwara, K.
  5. Gollerkeri, A.
  6. Gore, M.
  7. Houk, B.
  8. Lau, S.
  9. Poveda, A.
  10. González-Martín, A.
  11. Muller, C.
  12. Muro, K.
  13. Pierce, K.
  14. Suzuki, M.
  15. Vermette, J.
  16. Oza, A.
Journal:
Gynecologic Oncology

ISSN: 1095-6859 0090-8258

Year of publication: 2016

Volume: 142

Issue: 1

Pages: 62-69

Type: Article

DOI: 10.1016/J.YGYNO.2016.04.019 GOOGLE SCHOLAR

Sustainable development goals